VisionCare closes financing, makes board changes

Tuesday, January 24, 2012 12:51 PM

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, will close a Series E financing with Agate Medical Investments leading the expansion round.  Agate's managing general partner, Chanan Schneider, will join the VisionCare team as a board observer.

Allen W. Hill, VisionCare's CEO, said the financing will accelerate the commercial launch of its telescope implant for treating end-stage macular degeneration.

Schneider, managing general partner of Agate, previously was CEO of Beta-O2, a bio-device company, and managing director at Discount Capital Markets, where he led medtech and other technology investments.  

VisionCare also has added two new members to its board of directors: David Israeli, M.D., Pitango Venture Capital, and Yuval Avni, M.D., Giza Venture Capital.

Israeli joined Pitango in 2010 as a venture partner in the life sciences team, focusing on the medical device and biopharmaceuticals sectors. Previously, Israeli held positions at Medtronic and Rythmia Medical.

Avni is a partner at Giza Venture Capital, focusing on investments in life science and cleantech sectors. He is a medical practitioner with clinical experience in general and vascular surgery, and conducted clinical research in human genetics prior to entering the venture capital field.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs